Accordingly, CB1R antagonism has been identified as a therapeutic modality, as genetic deletion or pharmacological inhibition of CB1R prevents or attenuates PF development and progression in bleomycin-induced PF models (2, 3). Here, CNR1 is linked to pemphigus foliaceus.